key: cord-0685064-jmvozqsc authors: Morrison, Hamish D.; Cleaver, Jonathan; Lander, Natasha; Lowden, Philippa; Hale, Kate; Sharma, Kanchan; Stevens, James title: CANOMAD unmasked by COVID‐19 in a man with Waldenström's macroglobulinaemia date: 2021-08-12 journal: EJHaem DOI: 10.1002/jha2.210 sha: 1aea02997cf579e26dbe0e9e82e3aa25838931ec doc_id: 685064 cord_uid: jmvozqsc nan CANOMAD is a rare syndrome encompassing chronic ataxic neuropathy, ophthalmoplegia, IgM paraprotein, cold agglutinins and disialosyl antibodies [1, 2] . We present a case of acute craniobulbar palsy associated with COVID-19 in which the combination of an established IgM paraprotein and the later emergence of a typical and persistent ganglioside antibody profile ultimately revealed a diagnosis of CANOMAD syndrome. We review the clinical presentation, diagnostic work-up and current treatment. A 61-year-old right-handed male presented with a 24-h history of altered speech, diplopia, facial weakness and dysphagia pre- Figure 1 illustrates the clinical trajectory. CANOMAD is characterised by a chronic neuropathy with sensory ataxia and variable motor weakness, typically involving the ocular and bulbar muscles, occurring in the presence of monoclonal IgM directed against disialosyl ganglioside epitopes (GD1b, GD3, GT1b and GQ1b). Overt haematological malignancy is seen in around one-third. The associated neuropathy is often demyelinating, although not all neurophysiological testing will reveal this, such as in our case on initial testing. Ataxic neuropathy is frequently the dominant symptom, potentially causing severe disability. Disease trajectory is variable, typically extending over decades, with progression in two-thirds and a third relapsing-remitting [3] . Misdiagnosis is common, in part because fewer than half of the patients exhibit the full spectrum of clinical features, ultimately delaying appropriate treatment. Craniobulbar manifestations may be intermittent or persistent and often herald relapse, raising suspicion for CANOMAD in patients with an IgM paraprotein and undifferentiated neuropathy. Intercurrent infection is recognised as a trigger for CANOMAD relapse, although there remains limited published data to substantiate this [1] . Hitherto, this is the first reported case of CANOMAD relapse associated with COVID-19. Immune-mediated neuropathy and exacerbations of chronic neuromuscular disease have been described amongst possible complications of COVID-19 [4, 5] . However, other evidence implies a lack of causality, for example, between COVID-19 and GBS [6] . SARS-CoV-2 has the ability to bind to sialic acid containing glycoproteins and gangliosides often found on peripheral nerves [7] . Shared glycoprotein epitopes may have incited a high degree of specific immune stimulation, triggering the observed CANOMAD relapse. Positive GD1b antibodies in a Miller Fisher syndrome patient with COVID-19 may lend support to this theory of immune cross-reactivity between the SARS-CoV-2 spike and peripheral nerve gangliosides [8] . However, the specificity of this proposed immune response remains unproven. Neuropathy is present in up to 31% of patients with IgM monoclonal gammopathy and as many as 62.5% of patients with WM [9, 10] . There remains a lack of evidence-base for the treatment of CANOMAD. IVIg and rituximab are reportedly most efficacious, whereas corticosteroids and other forms of immunosuppression have little or unfavourable impact [3] . In this case, rituximab-administered for the haematological malignancy and associated neuropathy-likely had a stabilising effect on the neuropathy, in keeping with previously described cases [3, 12] . Whilst the CANOMAD acronym may prove a useful aide memoir, not Not applicable to this article as no datasets were generated or analysed during the current study. Hamish D. Morrison https://orcid.org/0000-0001-9358-7936 Jonathan Cleaver https://orcid.org/0000-0002-9657-5815 The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies Monoclonal IgM in a patient with paraproteinemic polyneuropathy binds to gangliosides containing disialosyl groups CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell-targeted therapies COVID-19-induced exacerbation of chronic inflammatory demyelinating polyneuropathy Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome Guillain-Barré syndrome: the first documented COVID-19-triggered autoimmune neurologic disease: more to come with myositis in the offing Miller Fisher syndrome and polyneuritis cranialis in COVID-19 Peripheral nervous system involvement in lymphomas Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies Investigation and management of IgM and Waldenströmassociated peripheral neuropathies: recommendations from the IWWM-8 consensus panel Successful treatment of CANOMAD with IVIg and rituximab CANOMAD unmasked by COVID-19 infection in a man with Waldenström's macroglobulinaemia. eJHaem